A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
Clinical trial NCT02383368 · COMPLETED
Trial details
- NCT number
- NCT02383368
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-23
- Primary completion
- 2018-04-27
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.